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Introduction: The asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO) is 
a clinical condition that combines features of those two diseases, and that is difficult to define 
due to the lack of understanding of the underlying mechanisms. Determining systemic media-
tors may help clarify the nature of inflammation in patients with ACO.
Objectives: We aimed at investigating the role and interaction of common markers of systemic 
inflammation (IL-6, IL-8, and tumor necrosis factor-α), Th2-related markers (periostin, IL-5, 
and IL-13), and IL-17 in asthma, COPD, and ACO.
Methods: This is a cross-sectional study of patients aged $40 years with a post-bronchodilator 
forced expiratory volume in the first second/forced vital capacity ,0.70 recruited from out-
patient clinics in tertiary hospitals with a clinical diagnosis of asthma, COPD, or ACO. ACO 
was defined by a history of smoking .10 pack-years in a patient with a previous diagnosis 
of asthma or by the presence of eosinophilia in a patient with a previous diagnosis of COPD. 
Clinical, functional, and inflammatory parameters were compared between categories using 
discriminant and network analysis.
Results: In total, 109 ACO, 89 COPD, and 94 asthma patients were included. Serum levels 
(median [interquartile range]) of IL-5 were higher in asthma patients than in COPD patients 
(2.09 [0.61–3.57] vs 1.11 [0.12–2.42] pg/mL, respectively; p=0.03), and IL-8 levels (median 
[interquartile range]) were higher in COPD patients than in asthma patients (9.45 [6.61–13.12] 
vs 7.03 [4.69–10.44] pg/mL, respectively; p,0.001). Their values in ACO were intermediate 
between those in asthma and in COPD. Principal component and network analysis showed a 
mixed inflammatory pattern in ACO in between asthma and COPD. IL-13 was the most con-
nected node in the network, with different weights among the three conditions.
Conclusion: Asthma and COPD are two different inflammatory conditions that may overlap in 
some patients, leading to a mixed inflammatory pattern. IL-13 could be central to the regulation 
of inflammation in these conditions.
Keywords: asthma mechanisms, COPD mechanisms, inflammatory cytokines, overlap, network 
analysis, IL-13
Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic 
inflammatory airway diseases with different underlying mechanisms.1 However, 
they are characterized by a complex heterogeneity and the existence of different 
overlapping phenotypes that influence the response to treatment. As a result, it is 
sometimes difficult to determine whether a patient is suffering from asthma, COPD, 
or the overlap of both the conditions. This controversy led to a theory – the so-called 
“Dutch hypothesis” – that postulates that chronic obstructive airway disease (COAD) 
may occur on a continuum, with “pure” forms of asthma and COPD representing 
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the extremes of the same disease and the various forms 
of COAD being different expressions of a single disease 
entity.2 To make things even more complicated, clinicians 
have long acknowledged the existence of a group of patients 
with COAD who display characteristics of both asthma and 
COPD. This condition has been recently regaining attention 
in the medical literature, and it has ended up being named 
ACO (asthma–COPD overlap).3,4 ACO is an umbrella term 
that encompasses patients with COPD and eosinophilic 
inflammation and smoking asthmatics with a predominantly 
neutrophilic inflammation and irreversible airway obstruc-
tion. Therefore, the whole picture of COAD is blurred, 
with different and overlapping phenotypes that are difficult 
to clinically distinguish from one to another with the lack 
of an accurate biomarker that is able to distinguish these 
entities. We have recently shown that the presence of a Th2 
signature, defined by eosinophils in sputum .3% or blood 
eosinophils .300 cells/µL, could help to identify and treat 
the patients with COAD.5
In a clinical scenario of great heterogeneity, breaking 
down complex data into its component parts and plotting 
them to show their interdependences and interrelationships 
would help us to clarify the motley nature of COAD. The 
aim of this study was to investigate the systemic “molecu-
lar fingerprinting” of the different clinical phenotypes of 
COAD. In doing so, the main objective was to evaluate the 
heterogeneity of inflammation in patients with COAD by 
using discriminant and network analysis. The comparison 
of correlation networks can provide new insights into the 
complexity and heterogeneity of ACO. As secondary end 
points, we assessed the capacity of these biomarkers to pre-
dict the clinical COAD phenotype, the Th2-high pattern, and 
the relation between these biomarkers and clinical significant 
outcomes: exacerbations and symptoms.
Materials and methods
Study design
This cross-sectional, observational, multicenter study was 
carried out in 23 outpatient clinics from tertiary hospitals 
in Spain run by expert respiratory physicians. The design 
of the study has been described elsewhere.5 As described in 
detail previously,5 “male and female patients aged $40 years 
with chronic airflow obstruction (post-bronchodilator 
forced expiratory volume in the first second (FEV
1
)/forced 
vital capacity (FVC) ,0.70) and a history of physician-
diagnosed asthma, COPD, or ACO (as defined below) who 
signed an informed consent form were included. Patients 
had to be in a stable condition and free from exacerbations 
for at least 3 months. Exclusion criteria included primary 
bronchiectasis, active cancer, other chronic inflammatory 
diseases, and poor performance status (defined as life expec-
tancy of ,3 months).”
A blood sample was obtained to determine the number 
and percentage of blood eosinophils and quantification of 
immunoglobulin E, and serum was stored at -80°C for 
later determination of periostin and cytokines. The degree 
of compliance with inhalers was estimated by the test of 
adherence to inhalers.6
The study was approved by the Research Ethics Commit-
tee of the Balearic Islands (code: IB2499/15). In addition, an 
independent ethics committee or institutional review board 
for each study center approved the final protocol.
Study protocol
All researchers were asked to recruit 12 consecutive patients 
with chronic obstructive airway disease: four nonsmoking 
asthmatics, four with COPD, two smoking asthmatics, and 
two with COPD with eosinophilia. The recruitment period 
was between October 2015 and March 2016. The flowchart 
of recruitment according to according to the STROBE state-
ment (STrengthening the Reporting of OBservational studies 
in Epidemiology) has been published elsewere.5
The study was conducted in a single visit in which 
the researchers obtained and recorded information in an 
electronic clinical research database: anthropometric data; 
smoking history; a previous history of atopy, rhinitis, nasal 
polyposis, and comorbidities; exacerbations in the previous 
year; symptoms assessed by the validated Spanish version 
of the COPD assessment test and by the asthma control 
test; pharmacologic treatments; and the degree of compli-
ance with inhalers estimated by the test of adherence to 
inhalers.
Fractional exhaled nitric oxide was measured by using a 
chemiluminescence analyzer (NIOX; Aerocrine, Stockholm, 
Sweden) at a flow rate of 50 mL/s, in accordance with the 
recommendations of the American Thoracic Society/the 
European Respiratory Society task force.
sputum induction
Before the induction of sputum, patients inhaled 400 µg of 
salbutamol. Briefly, the volume of the whole sputum was 
assessed, and an equal volume of dithioerythritol (Sigma, 
Munich, Germany) was added. The total cell count and viabil-
ity were obtained simultaneously in a modified Neubauer 
counting chamber (Hausser Scientific, Horsham, PA, USA). 
Differential cell counts were expressed as the percentage of 
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nonsquamous cells, and those with signifi cant squamous 
contamination (.80%) were excluded from the analysis.
sample size calculation
An a priori sample size was calculated considering a statisti-
cal power of 80% and 5% of alpha error. A minimum of 100 
asthma–COPD overlap (ACO) patients and 200 other chronic 
airway disease patients would be enough in order to identify 
statistically significant differences of $15% when compared 
with any of the reference groups, in most variables ranging 
from 10% up to 80% in ACO.
Definitions
asthma
Asthma with chronic airflow obstruction (post-bronchodilator 
FEV
1
/FVC ,0.70) was diagnosed according to the interna-
tional guidelines,7 and they were either never-smokers or 
ex-smokers with a smoking history of #10 pack-years.
COPD
COPD was diagnosed according to international recom-
mendations3 by the presence of post-bronchodilator FEV
1
/
FVC ,0.70 in patients with a smoking history of $10 pack-
years in the absence of a clinical suspicion for asthma.
aCO
As described in detail previously,5 we defined ACO as an 
umbrella term that encompasses two related – with a similar 
underlying mixed (Th2 and non-Th2) inflammatory pattern 
and chronic airflow obstruction – but distinct entities: smok-
ing asthmatics (SA; asthma with chronic airflow obstruction 
and a smoking history $20 pack-years) and COPD with 
eosinophilia (COPD-e; COPD patients with eosinophil 
count $200 cells/µL in blood). We selected this threshold 
because below this cutoff patients are unlikely to have sputum 
eosinophilia, according to published evidence.8
COaD with Th2-high
Patients with chronic airflow limitation demonstrated 
post-bronchodilator FEV
1
/FVC ,0.70 and a sign of 
Th2 inflammation as described previously5 (eosinophil 
count $300 eosinophils/µL in blood or $3% in sputum).
COaD with Th2-low
Patients with chronic airflow limitation demonstrated 
post-bronchodilator FEV
1
/FVC ,0.70 and no signs of 
Th-2 inflammation as described previously5 (eosinophil 
count #300 eosinophils/µL in blood and #3% in sputum).
Th2/Th1 ratio
The ratios IL-13/IL-8 or IL-5/IL-8 were calculated to detect 
a predominant Th2 profile.
Measurements
More detailed information about data management, pulmo-
nary function tests, fractional exhaled nitric oxide (FeNO) 
measurement, and cell inflammatory counts in induced 
sputum can be found elsewhere.5 Periostin levels were 
measured by using a streptavidin-horseradish peroxidase 
enzyme-linked immunosorbent assay (ELISA) commercial 
kit (DuoSet® ELISA; R&D Systems, Inc., Minneapolis, MN, 
USA), according to the manufacturer’s instructions. The 
specificity of the periostin assay was 100%, and the detec-
tion limit was 180 ng/mL. In all the patients, serum periostin 
levels were measured in duplicate.
The concentrations of IL-5, IL-13, IL-8, IL-6, tumor 
necrosis factor-α (TNF-α), and IL-17 in serum were ana-
lyzed by using a human cytokine magnetic bead panel 
(Merck Millipore, Billerica, MA, USA) according to the 
manufacturer’s instructions. Assay sensitivity according 
to the manufacturer was as follows: 0.23 pg/mL for IL-13, 
0.33 pg/mL for IL-17, 0.12 pg/mL for IL-5, 0.11 pg/mL for 
IL-6, 0.13 pg/mL for IL-8, and 0.16 pg/mL for TNF-α.
Network analysis
A network layout of the systemic inflammatory pattern 
(inflammome) in the three groups of participants was 
built following a previously validated method.9 Each node 
of the network represents one biomarker, its size being 
proportional to the percentage of the median in reference 
to maximal values for each variable. Nodes are linked if 
a statistically significant correlation (Spearman p,0.05) 
was found.
Statistical analysis
Data are expressed as mean (SD) for continuous normally 
distributed variables: univariate pair-wise comparisons were 
performed by using Student’s t-tests, while one-way analy-
sis of variance was used to compare more than two groups 
(Bonferroni correction was applied for pair-wise post hoc 
tests). Continuous variables with non-normal distributions 
were expressed as median (interquartile range [P25–P75]), 
and comparisons among groups were carried out by using 
the Mann–Whitney U-test or Kruskal–Wallis test with the 
Nemenyi post hoc test. For categorical variables, counts and 
percentages were given in each category, and groups were 
compared by means of χ2 tests, with Bonferroni correction 
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for pair-wise comparisons. Correlations between continuous 
variables were estimated by using Spearman test.
To explore the association of biomarkers with the COAD 
categories (asthma, COPD, and ACO) and to assess the cor-
responding discrimination ability, a discriminant analysis 
(DA) was carried out fitting the linear combinations of bio-
markers, which allowed the best classification of patients into 
the diagnostic groups. The results were visually summarized 
through a classification map, based on the DA estimates.
The reliability of biomarkers’ concentration for the diag-
nosis of different COAD categories and Th2 profiles was 
assessed by estimating the corresponding receiver operating 
characteristic (ROC) curves with the corresponding 95% 
confidence intervals. Youden index was used for the determi-
nation of optimal cutoff values of the biomarkers. Sensitivity 
and specificity were also estimated for each cutoff.
All statistical analyses were performed by using the 




As described in detail previously,5 292 patients with COAD 
were included in the study: 94 asthmatics, 89 COPD, and 109 
ACO (44 SA and 65 COPD-e) patients. Figure 1 shows the 
flowchart of patient recruitment. Table 1 reports the demo-
graphic, clinical, and functional characteristics of the entire 
sample. Briefly, patients showed a moderate degree of bron-
chial obstruction and mild-to-moderate level of symptoms 
as assessed by the COPD assessment test (CAT) and asthma 
control test (ACT) questionnaires. The average number of 
exacerbations during the last 12 months was 1.0. Baseline 
treatment was based on long-acting β
2
-agonist and inhaled 
corticosteroids (ICSs; 80%) and long-acting muscarinic 
antagonist (71%). All asthma patients, 66.3% of COPD 
patients, and 75% of ACO patients were treated with ICSs. 
No patient from the COPD or ACO group was being treated 
with oral corticosteroids, whereas 6.4% of the asthmatics 
were taking them. Interestingly, 17.5% of asthma patients and 
8.6% of ACO patients were receiving omalizumab.
Cytokine and periostin values among the 
different diagnostic categories
Table 2 and Figure 2 display the results of inflammatory 
markers measured in the three diagnostic categories. Th2-
related cytokines (IL-13 and IL-5) showed highest median 
values in asthma and lowest median values in COPD, whereas 
they presented intermediate results in ACO. The only statisti-
cally significant difference was in IL-5 levels between asthma 
Table 1 Characteristics of patients according to the baseline 
diagnosis




Age (years) 61.8 (12.3) 67.9 (8.6) 63.31 (10.6) ,0.001
Gender (% female) 55.3 24.7 34.9 ,0.001
BMI (kg/m2) 28.6 (4.7) 28.4 (4.9) 28.6 (6) 0.96
Pack-years 3.4 (5.8) 48.7 (22.5) 45.1 (24) ,0.001
Positive SPT (%) 46.8 7.9 32.1 ,0.001
Rhinitis (%) 53.2 9.3 31.1 ,0.001
Pre-BD FeV1 (%) 61.2 (17.7) 51.4 (18.2) 53.8 (16.5) ,0.001
Post-BD FeV1 (%) 69.5 (18.9) 55.1 (18.5) 58.9 (17) ,0.001
PBT (%) 44.6 19.2 37.7 0.001
DLCO (%) 83.4 (18.7) 63.6 (25.9) 66.6 (19.1) ,0.001
exacerbations in 
previous year
0.97 (1.37) 1.08 (1.32) 0.97 (1.36) 0.92
Blood eosinophils 
(cells/µL)
300 (0, 4,350) 100 (0, 200) 300 (0, 1,000) ,0.001
sputum eosinophils 
(n=35, %)
4.8 (5.8) 1.8 (2.1) 6.3 (5.8) 0.21
IgE (IU/mL) 123 (4, 2,909) 51 (4, 2,301) 89.8 (4, 2,500) 0.094
FeNO (ppb) 36.0 (24.1) 17.3 (9.6) 22.5 (21) ,0.001
CaT 14.8 (8.8) 13.0 (6.7) 13.3 (7.7) 0.83
aCT 20.2 (4.4) 20.4 (4.3) 19.4 (4.8) 0.54
ICS (%) 100 66.3 75.2 ,0.01
LABA (%) 99 93.3 93.6 0.19
LAMA (%) 54.3 87.6 73.4 ,0.01
Notes: Data are expressed as mean (SD), median (percentile 25, percentile 
75), or n and %. Overall p-values are reported. exacerbations: number of severe 
exacerbations during the past 12 months.
Abbreviations: aCO, asthma–COPD overlap; aCT, asthma control test; BMI, 
body mass index; CAT, COPD assessment test; COPD, chronic obstructive 
pulmonary disease; DLCO, carbon monoxide diffusing capacity; FeNO, fractioned 
exhaled nitric oxide levels; FeV1, forced expiratory volume in the first second; ICS, 
inhaled corticosteroid; Ige, immunoglobulin e; laBa, long-acting β2-agonists; laMa, 
long-acting muscarinic antagonists; PBT, positive bronchodilator test; post-BD, post-
bronchodilator; pre-BD, pre-bronchodilator; sPT, skin prick test.
Figure 1 Flowchart diagram of recruitment process.
Abbreviations: ACO, asthma–COPD overlap; COPD, chronic obstructive pulmo nary 
disease. FeV1, forced expiratory volume in the first second; FVC, forced vital capacity.
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and COPD (2.09 vs 1.11 pg/mL; p=0.03). IL-17 and TNF-α 
levels were similar between the groups. Periostin levels were 
not different between the three categories. Non-Th2-related 
cytokines such as IL-8 were found to be increased in COPD 
and ACO compared with asthma (p,0.001).
Th2/Th1 ratios (IL-5/IL-8 and IL-5/IL-13) were higher 
in asthma (0.25 and 0.43, respectively) than in the other 
categories without differences between ACO (0.14 and 0.14) 
and COPD (0.12 and 0.15).
Discriminant and network analysis
Overall, the correlation between the cytokines was poor. It is 
worth emphasizing that correlation between IL-5 and IL-13 
was 0.489 (p,0.0001), and IL-17 correlated moderately 
with IL-5 (r=0.553; p,0.0001), IL-13 (r=0.550; p,0.0001), 
and IL-6 (r=0.579; p,0.0001). IL-8 and TNF-α showed a 
weak correlation between them (r=0.207; p,0.0001) and 
no statistically significant correlation with IL-5, IL-13, and 
IL-17. IL-6 correlated moderately with the other cytokines. 
Blood eosinophils correlated weakly with IL-5 (r=0.122; 
p=0.40) and with periostin (r=0.211; p,0.0001). Periostin 
did not correlate significantly with blood cytokines.
Two principal components (linear combination of mark-
ers), explaining about 60% of the total variance in the data, 
were identified. The first discriminant score (DS1) was 
mainly characterized by the values of IL-5, IL-13, IL-6, and 
TNF-α, while IL-8 had more weight in the second discrimi-
nant score (DS2). Figure 3 shows the scatterplot of individual 
Table 2 Biomarker values according to the baseline diagnosis
Asthma (n=94) COPD (n=89) ACO (n=109) p-value
IL-6 (pg/mL) 1.77 (0.71–3.66) 1.13 (0.43–2.30)* 1.42 (0.57–2.44) 0.031
IL-8 (pg/mL) 7.03 (4.69–10.44) 9.45 (6.61–13.12)** 9.58 (6.39–13.51)** ,0.001
TnF-α (pg/mL) 3.93 (3.11–5.50) 4.21 (2.57–5.68) 4.17 (3.22–5.43) 0.660
IL-13 (pg/mL) 2.98 (0.23–7.63) 1.25 (0.23–5.31) 1.98 (0.23–9.92) 0.213
IL-5 (pg/mL) 2.09 (0.61–3.57) 1.11 (0.12–2.42)* 1.73 (0.41–2.77) 0.012
Periostin (ng/mL) 37.4 (26.6–49.2) 33.5 (27.7–49.9) 35 (27.9–44) 0.232
IL-17 (pg/mL) 6.94 (3.11–15.90) 5.33 (1.41–11.37) 6.75 (2.64–12.47) 0.075
Il-13/Il-8 0.43 (0.05–0.63) 0.15 (0.04–0.56) 0.14 (0.03–0.53) 0.013
Il-5/Il-8 0.25 (0.08–0.63) 0.12 (0.02–0.25) 0.14 (0.05–0.29) ,0.001
FeNO (ppb) 33 (19.8–41.3) 17.3 (12–18.8)** 19.6 (10–24.6)** ,0.001
Notes: Overall p-values from Kruskal–Wallis anOVa; pairwise p-values from Mann–Whitney U-test, Bonferroni-corrected: *p,0.05 vs asthma; **p,0.001 vs asthma.
Abbreviations: ACO, asthma–COPD overlap; ANOVA, analysis of variance; COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; TNF-α, 
tumor necrosis factor-α.
α
Figure 2 Cytokine concentrations in asthma, ACO, and COPD.
Notes: *p,0.05 vs asthma; **p,0.001 vs asthma.
Abbreviations: aCO, asthma–COPD overlap; COPD, chronic obstructive pulmo-
nary disease; TNF-α, tumor necrosis factor-α.
Figure 3 scatterplot of the combination of values from discriminant scores 1 and 2 
as compared to each patient’s COAD category.
Abbreviations: COAD, chronic obstructive airway disease; COPD, chronic 
obstructive pulmonary disease; COPD-e, COPD with eosinophilia; NSA, nonsmoking 
asthmatics; sa, smoking asthmatics.
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Figure 4 Network layout of inflammome in asthma, COPD, and ACO.
Abbreviations: ACO, asthma–COPD overlap; COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; TNF-α, tumor necrosis factor-α.
α
α α
values computed for each patient based on DS1 and DS2, 
identifying the patient’s diagnostic category (asthma, COPD, 
and ACO). Patients from different categories had very similar 
DS values, so that a clear and distinct pattern could not be 
observed in cytokine relationship. Less than one half of the 
patients (42.8%) were correctly classified by the two esti-
mated DSs, confirming the limited discrimination abilities 
of these markers.
The network representation of the weight and interac-
tion of inflammatory markers (inflammome) in the three 
categories yielded two different scenarios, being IL-13 and 
IL-17 the most connected nodes but with different weights 
of the nodes, showing IL-5 and IL-8 with the most marked 
differences in node weight. The inflammome of ACO was a 
mixture of the two previous networks, being IL-5 and IL-8 
equally important and with IL-13 and IL-17 still in the middle 
of the network (Figure 4).
Diagnostic accuracy of the potential 
biomarkers for the identification of 
different diagnostic categories or 
Th2-high and Th2-low inflammatory 
phenotypes
Neither a single cytokine nor Th2/Th1 ratios yielded enough 
sensitivity and specificity to accurately identify the various 
diagnostic categories of COAD (asthma, COPD, and ACO). 
The area under the ROC curve (AUC) was ,0.7 in every 
case. Table S1 displays the AUCs for each cytokine or 
periostin and the diagnostic categories of COAD.
Some cytokines were more highly expressed in the Th2-
high group compared with the Th2-low group (Table 3), 
medians (interquartile ranges): IL-5 (1.96 [0.87–3.34] vs 
1.51 [0.29–2.88] pg/mL; p=0.025), TNF-α (4.32 [3.20–6.16] 
vs 3.95 [2.91–5.32] pg/mL; p=0.055), and periostin (39.73 
[28.05–54.40] vs 34.20 [26.94–41.43] ng/mL; p=0.005). 
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No statistically significant differences were found between 
the two groups in the other analyzed cytokines, alone or in 
combination (Table 3).
Again, since the AUC was ,0.7 in every case, neither a 
single cytokine nor periostin, nor any combination of them, 
yielded enough sensitivity and specificity to accurately 
predict the Th2-high and Th2-low molecular phenotype. 
A cutoff value of FeNO .17 ppb showed better AUC (0.707 
[0.642–0.772], p,0.001) than the cytokines or periostin in 
blood (Table 4).
Association of cytokines or periostin 
with clinical outcomes
The values of the different cytokines or periostin (alone 
or in combination) were not different between the patients 
with (n=144) and without (n=148) exacerbations, between 
poorly controlled (ACT ,20 [n=85]) and well-controlled 
asthmatics (ACT $20 [n=137]), between symptomatic 
(CAT $10 [n=163]) and poorly symptomatic COPD patients 
(CAT ,10 [n=81]), and between those with FEV
1
 above the 





In this study, we have found that the different inflammatory 
mechanisms involved in asthma and COPD may overlap in 
certain patients, leading to a mixture of Th2 and non-Th2 
cytokine expression. ACO shows therefore a heterogeneous 
inflammatory process that overlaps the characteristics of 
both conditions: asthma and COPD; therefore, it cannot be 
considered a specific phenotype of any of them. As expected, 
Th2-related cytokines (IL-13 and IL-5) exhibited highest 
median values in asthma and lowest median values in COPD 
with intermediate results in ACO. Inversely, IL-8 was found 
to be significantly increased in patients with a smoking his-
tory (COPD and ACO) in comparison with asthma. Periostin 
levels were not useful to distinguish between categories, but 
they were increased in those with a more predictable “Th2-
high signature” (asthma and ACO) with respect to COPD. 
Interestingly, IL-13 was the most connected node of the 
inflammome in the three conditions. Taken together, these 
findings are congruent with the heterogeneous inflammatory 
background of COAD patients, probably a continuum 
between non-Th2 and Th2 inflammation with substantial 
overlap in a high proportion of cases.
Since several biologic therapies are now being tested in 
asthma and COPD, the identification of biological markers 
reflecting the underlying disease process seems to be of 
particular relevance to implementing more personalized 
approaches to therapeutic decisions in airway disease. How-
ever, to date, very few studies have addressed the underlying 
mechanisms of inflammation in ACO. Kitaguchi et al,10 in a 
retrospective study with a small sample size, found that COPD 
patients with asthmatic symptoms had high peripheral and 
sputum eosinophil counts and better reversibility response 
to treatment with ICSs. On the other hand, Gao et al11 aimed 
at finding sputum biomarkers capable of differentiating 
between ACO, COPD, and asthma patients. They found 
that only sputum neutrophil gelatinase-associated lipocalin 
levels were significantly increased in patients with ACO in 
comparison with the asthma and COPD groups. In this study, 
sputum IL-13 was increased in asthma, COPD, and ACO in 
comparison with healthy and smoker controls, which could 
Table 3 Blood biomarkers in Th2-high and Th2-low patients
Th2-high pattern  
(n=94)
Th2-low pattern  
(n=197)
p-value
IL-6 (pg/mL) 1.75 (0.58–2.67) 1.31 (0.50–2.63) 0.174
IL-8 (pg/mL) 8.34 (5.37–12.77) 8.40 (5.88–12.77) 0.856
TnF-α (pg/mL) 4.32 (3.20–6.16) 3.95 (2.91–5.32) 0.055
IL-13 (pg/mL) 2.92 (0.26–5.59) 1.65 (0.23–5.58) 0.150
IL-5 (pg/mL) 1.96 (0.87–3.34) 1.51 (0.29–2.88) 0.025
Periostin (ng/mL) 39.73 (28.05–54.40) 34.20 (26.94–41.43) 0.005
Il-13/Il-8 0.26 (0.06–0.66) 0.15 (0.03–0.78) 0.182
Il-5/Il-8 0.23 (0.08–0.40) 0.13 (0.03–0.33) 0.019
IL-17 (pg/mL) 7.37 (3.46–13.76) 5.73 (2.10–12.12) 0.125
Notes: Data are expressed as medians and interquartile ranges; p-values from the 
Mann–Whitney U-test.
Abbreviation: TnF-α, tumor necrosis factor-α.
Table 4 Biomarker rOC and best cutoff point to predict Th2-
high or Th2-low patterns
Biomarker ROC Value
Il-6 AUC (95% CI) 0.550 (0.479–0.620)
Best cutoff (pg/mL) na
Il-8 AUC (95% CI) 0.507 (0.434–0.579)
Best cutoff (pg/mL) na
TnF-α AUC (95% CI) 0.570 (0.499–0.641)
Best cutoff (pg/mL) 4.04
Il-13 AUC (95% CI) 0.552 (0.482–0.623)
Best cutoff (pg/mL) na
Il-5 AUC (95% CI) 0.582 (0.512–0.652)
Best cutoff (pg/mL) 1.79
Periostin AUC (95% CI) 0.602 (0.528–0.677)
Best cutoff (IU/mL) 35.2
Il-5 + Il-13 AUC (95% CI) 0.579 (0.508–0.650)
Il-5 + Il-13 + Il-8 AUC (95% CI) 0.593 (0.523–0.662)
Il-13/Il-8 AUC (95% CI) 0.549 (0.479–0.619)
Il-5/Il-8 AUC (95% CI) 0.586 (0.517–0.654)
Best cutoff 0.15
Il-17 AUC (95% CI) 0.556 (0.486–0.626)
Best cutoff (pg/mL) na
Abbreviations: AUC, area under the ROC; CI, confidence interval; NA, not 
applicable; rOC, receiver operating curve; TnF-α, tumor necrosis factor-α.
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be sustaining the central role in the inflammome we found 
in our study. However, since the definitions of the different 
diagnostic categories are somewhat arbitrary and based on 
nonspecific clinical features, the design of this study was sub-
jected to the same limitations as all the previously published 
studies on this topic. In theory, it would be expected to find 
some evidence of Th1 inflammation (characteristic, but 
not pathognomonic of COPD) and some evidence of Th2 
inflammation (characteristic, but not pathognomonic of 
asthma) in patients with ACO.12 Unfortunately, there is a 
lack of reliable Th1 biomarkers; therefore, we have to rely 
on the assumption that individuals with a smoking history 
and “fixed bronchial obstruction” who show some evidence 
of Th2 inflammation can accurately be classified as ACO.13 
Our finding of intermediate IL-5 and IL-13 levels in ACO 
categories, when compared to asthma and COPD, could give 
some support to this hypothesis.
Based on DA results, we were unable to find meaning-
ful clusters of association between the different biomarkers, 
and in consequence, we were not able to demonstrate a link 
between the three clinical categories of COAD (asthma, 
COPD, and ACO) with clearly defined different inflam-
matory patterns. However, a network representation of the 
interaction between the inflammatory markers yielded two 
clearly different networks that overlap in ACO. This supports 
the hypothesis that inflammatory pattern observed in ACO 
is a blend of COPD and asthma components.
Overall, the correlation between biomarkers was poor. 
The weak correlation found between blood eosinophils 
and Th2-high cytokines (IL-5 and IL-13) was of particu-
lar interest because it contradicts the results obtained by 
Agache et al,14 who observed an almost perfect (r.0.90) 
association between these variables in 64 adult asthmatics. 
Our results were not different when we analyzed separately 
the correlation of these biomarkers in the asthma group, 
although it should be taken into account that all of our 
patients showed “fixed bronchial obstruction,” whereas 
this feature was only present in 6% of Agache et al’s 
sample, which might reflect notable differences in the 
studied populations.
Two reasons could help to explain the observed lack 
of association between clinical categories and putative 
biomarkers. First, it has been reported that asthma and 
COPD demonstrate a significant overlap in the airway 
cytokine profile, which suggests the coexistence of dif-
ferent phenotypes of COAD sharing a common cytokine 
network.15,16 The central role of IL-13 and IL-17 in the 
network would be in keeping with this result. Moreover, 
we should bear in mind that asthma and COPD are 
themselves heterogeneous diseases with various inflam-
matory phenotypes. Solleiro-Villavicencio et al17 observed 
that the inflammatory response induced by the exposure to 
biomass smoke differs greatly from that caused by tobacco 
smoking, and Khurana et al18 found that “COPD persistent 
sputum producers” have increased concentrations of some 
inflammatory mediators in the airways when compared to 
nonpersistent sputum producers. On the other hand, Seys 
et al19 found five different asthma clusters based on sputum 
cytokine expression, which underscores the heterogeneity in 
airway inflammation among different asthma patients. Taken 
together, these studies point out a patient-to-patient variabil-
ity of the inflammatory markers in individuals with COAD. 
Second, there seems to be no clear correlation between bio-
markers in systemic and pulmonary compartments. Although 
serum cytokines have shown sufficient reliability and repeat-
ability over time, several authors observed only few and 
weak associations between lung and serum biomarkers, both 
in COPD20,21 and asthma patients.22 Thus, it is possible that 
measuring serum cytokines does not sufficiently reflect the 
inflammatory processes within the airways.
As described in detail previously,5 “our work has several 
limitations that deserve a comment. First, we used arbitrary 
cutoff points of blood eosinophil to recruit patients and to 
define Th2 profile, but we used the available published infor-
mation that supports this view. However, we were more strin-
gent in the definition of Th2, using a cutoff of 300 cells/µL, 
which is widely accepted.23 In addition, a large number of 
patients were receiving ICSs, and some of them were being 
treated with oral corticosteroids or omalizumab, which could 
have an effect masking differences between groups and 
modifying the expression of Th2 biomarkers such as blood/
sputum eosinophils and serum cytokines. Third, the limit of 
20 pack-years of smoking exposure in asthmatics could be 
too artificially high. However, by doing so, we make sure 
that this phenotype is going to overlap the characteristics 
of smoking-related inflammation on the top of the baseline 
asthmatic inflammation.”
Conclusion
The heterogeneity of asthma and COPD induces different 
inflammatory pathways that coexist in ACO, being IL-13 the 
common node orchestrating the inflammome in these condi-
tions. Nevertheless, neither non-Th2-related nor Th2-related 
serum cytokines or periostin (alone or combined) permitted 
to distinguish between COAD categories or to predict a Th2-
high inflammatory pattern.




Th2 and non-Th2 inflammatory pattern in ACO
Acknowledgments
The authors are grateful to all the patients who participated 
in the study. A number of investigators contributed to the 
study logistics and they are listed in the Supplementary 
materials. The project was endorsed by the COPD and 
Asthma Research Board (PII de EPOC y asma) of the Spanish 
Society of Pneumology and Thoracic Surgery (SEPAR). The 
project was partially funded by the Fondo de Investigaciones 
Sanitarias, Instituto de Salud Carlos III, Ministerio de Eco-
nomia y Competitividad (FIS 15/01263) through European 
Union FEDER funds and by unrestricted grant from Chiesi 
España S.A.U.
Author contributions
All the authors made substantial contributions to conception 
and design, acquisition of data, or analysis and interpretation 
of data; drafted the article and revised it critically for impor-
tant intellectual content; gave the final approval of the version 
to be published; and agreed to be accountable for all aspects of 
the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated 
and resolved. More specifically, BGC and LPL designed the 
study, recruited patients, analyzed the results, and wrote the 
manuscript. AI, NdC, and CC performed the cytokine analy-
sis. ALV, AT, JLLC, JBS, EMM, JLI, IB, VP, MM, and JJSC 
recruited patients and reviewed the manuscript. The rest of 
the CHACOS study team recruited patients.
Disclosure
Dr Pérez de Llano reports grants from SEPAR, during the 
conduct of the study, and grants and personal fees from 
Novartis, Chiesi, AstraZeneca, and Pfizer, outside the 
submitted work. Dr Cosío reports grants from SEPAR, 
during the conduct of the study, and personal fees from 
AstraZeneca, grants from Boehringer Ingelheim, grants and 
personal fees from Novartis, Chiesi, Rovi, Menarini, and 
Esteve, outside the submitted work. Dr Izquierdo reports 
and has received funds for advisory boards and lectures 
from Almirall, AstraZeneca, Bayer, GlaxoSmithKline, 
Novartis, Pfizer, Boehringer Ingelheim, Takeda, Chiesi, and 
Menarini. Dr Soler-Cataluña reports grants from SEPAR, 
during the conduct of the study and grants and personal fees 
from AstraZeneca, Boehringer Ingelheim, Novartis, Chiesi, 
Rovi, Menarini, and Esteve, outside the submitted work. 
Dr Miravitlles reports personal fees from Almirall, Boehringer 
Ingelheim, AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, 
Teva, Grifols, and Novartis, outside the submitted work. The 
authors report no other conflicts of interest in this work.
References
 1. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary 
disease. Nat Rev Immunol. 2008;8(3):183–192.
 2. Orie NG, Slutter HJ, de Vries, Tammeling GJ. [Chronic nonspecific 
respiratory diseases]. Ned Tijdschr Geneeskd. 1961;105:2136–2139. 
Dutch.
 3. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Lung 
Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol. 
2017;53(3):128–149. English, Spanish.
 4. Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the 
asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016; 
149(1):45–52.
 5. Cosio BG, Pérez de Llano L, Lopez Viña A, et al. Th-2 signature 
in chronic airway diseases: towards the extinction of asthma-COPD 
overlap syndrome? Eur Respir J. 2017;49(5):pii:1602397.
 6. Plaza V, Fernandez-Rodriguez C, Melero C, et al. Validation of the ‘Test 
of the Adherence to Inhalers’ (TAI) for asthma and COPD patients. 
J Aerosol Med Pulm Drug Deliv. 2016;29(2):142–152.
 7. Global Ini tiative for Asthma (GINA). Global Strategy for Asthma Man-
agement and Prevention; updated 2017. Available from: http://ginasthma.
org/2017-gina-report-global-strategy-for-asthma-management-and-
prevention/ Chapter 1, page 14. Accessed 17 January 17, 2018.
 8. Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosino-
phils: a surrogate marker for airway eosinophilia in stable COPD. Int 
J Chron Obstruct Pulmon Dis. 2016;11:1495–1504.
 9. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflam-
mation is associated with poor clinical outcomes in COPD: a novel 
phenotype. PLoS One. 2012;7(5):e37483.
 10. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum 
eosinophilia can predict responsiveness to inhaled corticosteroid treat-
ment in patients with overlap syndrome of COPD and asthma. Int J 
Chron Obstruct Pulmon Dis. 2012;7:283–289.
 11. Gao J, Iwamoto H, Koskela J, et al. Characterization of sputum biomark-
ers for asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon 
Dis. 2016;11:2457–2465.
 12. Pérez de Llano LA, Cosio BG. Asthma, chronic obstructive pulmonary 
disease and other combinations. Arch Bronconeumol. 2016;52(10): 
499–500. English, Spanish.
 13. Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for 
identification of asthma-COPD overlap: consensus between the Spanish 
COPD and asthma guidelines. Eur Respir J. 2017;49(5):pii: 1700068.
 14. Agache I, Strasser DS, Klenk A, et al. Serum IL-5 and IL-13 consistently 
serve as the best predictors for the blood eosinophilia phenotype in adult 
asthmatics. Allergy. 2016;71(8):1192–1202.
 15. Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports 
both “Dutch” and “British” hypotheses of asthma and chronic obstruc-
tive pulmonary disease. J Allergy Clin Immunol. 2015;135(1):63–72.
 16. Paplinska-Goryca M, Nejman-Gryz P, Gorska K, Bialek-Gosk K, 
Hermanowicz-Salamon J, Krenke R. Expression of inflammatory 
mediators in induced sputum: comparative study in asthma and COPD. 
Adv Exp Med Biol. Epub 2016 Oct 14.
 17. Solleiro-Villavicencio H, Quintana-Carrillo R, Falfan-Valencia R, 
Vargas-Rojas MI. Chronic obstructive pulmonary disease induced by 
exposure to biomass smoke is associated with a Th2 cytokine produc-
tion profile. Clin Immunol. 2015;161(2):150–155.
 18. Khurana S, Ravi A, Sutula J, et al. Clinical characteristics and airway 
inflammation profile of COPD persistent sputum producers. Respir 
Med. 2014;108(12):1761–1770.
 19. Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum 
cytokine-high profiles reveals diversity in T(h)2-high asthma patients. 
Respir Res. 2017;18(1):39.
 20. Ropcke S, Holz O, Lauer G, et al. Repeatability of and relationship 
between potential COPD biomarkers in bronchoalveolar lavage, 
bronchial biopsies, serum, and induced sputum. PLoS One. 2012; 
7(10):e46207.




Pérez de llano et al
 21. Nunez B, Sauleda J, Garcia-Aymerich J, et al. Lack of correlation 
between pulmonary and systemic inflammation markers in patients 
with chronic obstructive pulmonary disease: a simultaneous, two-
compartmental analysis. Arch Bronconeumol. 2016;52(7):361–367. 
English, Spanish.
 22. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma 
therapy? Lancet Respir Med. 2015;3(11):824–825.
 23. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD 
overlap. Clinical relevance of genomic signatures of type 2 inflamma-
tion in chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med. 2015;191(7):758–766.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.





Th2 and non-Th2 inflammatory pattern in ACO
Supplementary materials
authorship
Members of the CHACOS Study Group
DUE Rocio Cordova, Hospital Universitario Son Espases-
IdISPa, CIBERES, Palma de Mallorca, Spain; Dr Sergi 
Pascual, Dra Mireia Admetlló, Hospital del Mar, Barcelona, 
Spain; Dra Salud Santos, Dr Gianluca Cotta Ramusino, 
Hospital Universitari de Bellvitge, Barcelona, Spain; Dra 
Carmen Gómez Neira, Dra Irene Carla Martin Robles, Hos-
pital Universitario Lucus Augusti, Lugo, Spain; Dr Alberto 
Fernández-Villar, Dra Cristina Represas, Dra Ana Priegue 
Carreracon Hospital Xeneral de Vigo, Vigo, Spain; Dra 
Andrea Trisán Alonso Hospital Puerta del Hierro, Madrid, 
Spain; Dr Francisco García Río, Dr Raúl Galera Martínez, 
Dra Raquel Casitas Mateo, Dra Elisabet Martínez Cerón, 
Hospital La Paz, Madrid, Spain; Dra Sagrario Mayoralas, 
Dr Adalberto Pacheco Galván, Hospital Universitario 
Ramón y Cajal, Madrid, Spain; Dr Luis Puente Maestu, 
Dra Julia Garcia de Pedro, Dra Pilar Sanz, Hospital Gen-
eral Universitario Gregorio Marañón, Madrid, Spain; 
Dr José Belda Ramírez, Dr Fernando Sánchez-Toril López, 
Dr Rafael Peris Cardells, Hospital Arnau de Vilanova, Valencia, 
Spain; Dra Maria Climent Gregori, Hospital Universitario 
Dr Peset, Valencia, Spain; Dra Patricia Garcia-Sidro, Hos-
pital Castellón de la Plana, Castellón, Spain; Dra Cleofe 
Fernández, Dra Maria Encarnación Barroso Medel, Hos-
pital General Universitario de Alicante, Alicante, Spain; 
Dra María Abad Arranz, Dr Eduardo Márquez Martín, Dr 
Francisco Ortega, Ruiz Hospital Virgen del Rocío, Sevilla, 
Spain; Dr Bernardino Alcazar, Hospital Alta Resolución 
de la Loja, Granada, Spain; Dr Javier Calleja, Raúl Godoy 
Mayoral, Javier Cruz Ruiz, Hospital General Universitario 
de Albacete, Albacete, Spain; Dra Nuria Marina Malanda, 
Table S1 Biomarker AUC in the ROC for the diagnosis of the 
different COaD categories, alone and in combination
Biomarker Asthma COPD ACO






















































Note: Data shown as area under the curve (confidence interval 95%).
Abbreviations: ACO, asthma–COPD overlap; AUC, area under the ROC; COAD, 
chronic obstructive airway disease; COPD, chronic obstructive pulmonary disease; 
rOC, receiver operating curve; TnF-α, tumor necrosis factor-α.
Dr Juan Bautista Gáldiz Iturri, Dra Elena López de Santa 
Maria Miró, Hospital Universitario Cruces, Bilbao, Spain; Dr 
Juan Luis García Rivero, Dra Ruth Valerie Alain Mbessekg, 
Hospital de Laredo, Laredo, Spain; Dra Cristina Martinez, 
Dra Rosirys Mercedes Guzmán Taveras, Dra Ana Fernandez 
Tena, Dra Rosario Madiedo de la Llera, Dra Ángeles Encar-
nación Malmierca de Dios, Instituto Nacional de Silicosis, 
Oviedo, Spain; Dr Jose Antonio Ros Lucas, Dra M Carmen 
Soto Fernández, Dr Rubén Andújar Espinosa, Hospital Uni-
versitario Virgen de la Arrixaca, Murcia, Spain; Dra Míriam 
Barrecheguren, Dra Cristina Esquinas, Hospital Universitari 
Vall d’Hebrón, Barcelona, Spain.
